Clare Bradley, Jan Mitchell and Alison Woodcock (2009) The MacDQol individualized measure of the impact of macular disease on quality of life In: Handbook of Disease Burdens and Quality of Life Measures. , New York, pp. 247-263.
Full text access: Open
The MacDQOL is an individualized measure of the impact of macular disease (MD) on quality of life. It was designed with reference to people who had MD, using focus groups, and to the literature. An early draft was pilot tested with a postal study in which participants (N = 65) were recruited from the membership of the UK Macular Disease Society. This study showed significant differences in MacDQOL scores between people who were not registered and those who were registered blind (p < 0.001) or partially sighted (p < 0.001) and the findings offered early evidence of construct validity. There followed a longitudinal study (N = 156) to enable further validation of the MacDQOL. Participants were recruited from an ophthalmic specialist’s patient list. Principal components analysis revealed a single scale with excellent internal consistency reliability (Cronbach’s alpha = 0.946). Test-retest reliability was excellent with MacDQOL scores at time 1 and time 2 highly correlated (r = 0.946) and no differences in scores between time 1 and time 2 (p = 0.85). Construct validity was demonstrated by the MacDQOL’s sensitivity to several measures of vision (near and distance visual acuity, contrast sensitivity, reading speed, color recognition). There was some correlational evidence of responsiveness to change in vision over time. Good response rates and completion rates indicated that the MacDQOL is acceptable to participants and does not impose too great a burden. The MacDQOL has been used in clinical trials and a number of other studies. Evidence to date indicates that MD has a negative impact on the quality of life of people with the condition and that the negative impact increases with increasing severity of MD. The MacDQOL promises to be a valuable tool in the investigation of changes in patients’ quality of life in clinical trials of medical treatments and rehabilitative interventions.
This is a Draft version This version's date is: 30/09/2009 This item is peer reviewed
https://repository.royalholloway.ac.uk/items/66cb1348-ffcb-ff07-c1e0-5cba4b8fec1c/1/
Deposited by () on 12-May-2010 in Royal Holloway Research Online.Last modified on 12-May-2010
(C) 2009 Springer New York, whose permission to mount this version for private study and research is acknowledged. The repository version is the author's final draft.
Bailey IL, Bullimore MA, Raasch TW, Taylor HR. (1991). Invest Ophthalmol Vis Sci. 32: 422–432. Berdeaux G, Mesbah M, Bradley C. (2006). Value Health. 9: A372–A373. Bradley C. (1997). Adv Perit Dial. 13: 116–120. Bradley C. (2001). Lancet. 357(9249): 7–8. Bradley C, Speight J. (2002). Diabetes Metab Res Rev. 18 Suppl 3: S64–69. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. (1999). Qual Life Res. 8: 79–91. Brose L, Watkins J, Bradley C. (2007). 2007 International Society for Quality of Life Research meeting abstracts (www.isoqol.org/2007mtgabstracts). The QLR Journal. A-60, Abstract 1198. Chisholm IH. (1998). Optom Today. August 1998: 39–42. Covert D, Berdeaux G, Mitchell J, Bradley C, Barnes R. (2007). Surv Ophthalmol. 52: S20–S25. DAFNE Study Group. (2002). BMJ. 325: 746–749. de Boer MR, Moll AC, de Vet HC, Terwee CB, Volker-Dieben HJ, van Rens GH. (2004). Ophthalmic Physiol Opt. 24: 257–273. Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. (2004). Arch Ophthalmol. 122: 564–572. Frost NA, Sparrow JM, Hopper CD, Peters TJ. (2001). Ophthalmic Epidemiol. 8: 1–11. Gill TM, Feinstein AR. (1994). JAMA. 272: 619–626. Joyce CRB. (1994). In: McGee HM, Bradley C (eds.). Quality of Life Following Renal Failure: Psychosocial Challenges Accompanying High Technology Medicine. Harwood Academic, Chur, Switzerland, pp. 43–54. Kaiser PK, Do DV. (2007). Int J Clin Pract. 61: 501–509. Kinmonth AL, Woodcock A, Griffin S, Spiegal N, Campbell MJ. (1998). BMJ. 317: 1202–1208. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. (2001). Arch Ophthalmol. 119: 1050–1058. Mangione CM, Phillips RS, Seddon JM, Lawrence MG, Cook EF, Dailey R, et al. (1992). Med Care. 30: 1111–1126. McGee HM, O’Boyle CA, Hickey A, O’Malley K, Joyce CR. (1991). Psychol Med. 21: 749–759. McMillan C, Bradley C, Razvi S, Weaver J. (2008). Value Health. 11(2): 285–294. McMillan CV, Bradley C, Gibney J, Russell-Jones DL, Sonksen PH. (2006). J Eval Clin Pract. 12: 501–514. McMillan CV, Bradley C, Giannoulis M, Martin F, Sonksen PH. (2003). Health Qual Life Outcomes, 1: 51. McMillan CV, Honeyford RJ, Datta J, Madge NJ, Bradley C. (2004). Health Qual Life Outcomes. 2: 61. Mitchell J, Bradley C. (2004). Qual Life Res. 13: 1163–1175. Mitchell J, Bradley P, Anderson SJ, ffytche T, Bradley C. (2002). Br J Ophthalmol. 86: 777–781. Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, ffytche T, Rubinstein M, et al. (2008). Am J Ophthalmol, 146: 447–454. Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, McMillan CV, ffytche T, et al. (2005). Health Qual Life Outcomes. 3: 25. Mitchell J, Woodcock A, Bradley C. (2004). Qual Life Res, 13: 1548 (abstract). National Statistics Online. (2004). Population Estimates. Available at: http://www.statistics.gov.uk/CCI/nugget.asp?ID=6. Nobre F, Trotta L, Gomes L. (1999). Stat Med. 18: 3345–3354. Oppenheim A. (1968). Questionnaire Design and Attitude Measurement. Heinemann Educational, London. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. (2003). Br J Ophthalmol. 87: 312–317. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. (2004). Bull World Health Org. 82: 844–851. Ruta DA, Garratt AM, Russell IT. (1999). Qual Health Care. 8: 22–29. Speight J, Amiel S, Bradley C, Heller S, James P, Oliver L, et al. (2007). Diabetic Med. 24(Suppl 1): 95, 224. Speight J, Woodcock A, Plowright R, Bradley C. (2003). Qual Life Res. 12: 863. Wee HL, Tan CE, Goh SY, Li SC. (2006). Pharmacoeconomics. 24: 673–682. WHO. (2004). Magnitude and causes of visual impairment. Available at: http://www.who.int/mediacentre/factsheets.fs282/en, retrieved on 12 March, 2006. Wilson RJ, Christie MJ, Bradley C. (1998). Diabetic Med. 15(Suppl 2): 122–123. Wolffsohn JS, Cochrane AL. (2000). Am J Ophthalmol. 130: 793–802. Wolffsohn JS, Cochrane AL, Watt NA. (2000). Br J Ophthalmol. 84: 1035–1040. Woodcock A, Bradley C, Plowright R, ffytche T, Kennedy-Martin T, Hirsch A. (2004). Patient Educ Couns. 53: 365–383. Woodcock AJ, Julious SA, Kinmonth AL, Campbell MJ. (2001). Qual Life Res. 10: 661–670.